Hi Hopkirk as always a balanced resume - my only comment being whilst I accept Sar are equal in partnership they have the "goose" that hopefully is the "golden egg" so the next round of funding I would like to see BACIT take more of a role in raising funds that's a benefit for all - obviously depends on how confident all 3 partners are going into Phase 1 trails, which in itself should lift sp
....and would love to hear update from China......
Hi. There are still lots of unknowns. If CHK1 gets to Phase 1 trials (not guaranteed but no news is good news at this point), the price should go up as it will a) increase the chances of a deal and b) make the value of that deal more rewarding.
But then there is the question of actually funding the trials. CHK1 will probably cost SAR 1.3m (if they pay the same as BACIT which seems logical to me).
So although applying for trials and then trials starting will be a massive boost for SAR, it opens up more doubt about financing. IMO this is what is keeping it low at the moment - If CHK1 gets to trials, there could be another big placing to raise the cash which could push the SP down to 0.3p. It would be good for the company (in a strange way as it needs to happen and without it the value would go down anyway) but bad for existing shareholders in the short term.
Being more optimistic, the TYK2 results are due soon and Tim is back in San Diego for the recently added Bio International event. Maybe this is a coincidence. Maybe just my wishful thinking. But an early stage deal on this takes away the financing problem.
But until there is more clarity, the questions remain and as long as there is doubt, the price will be low.
So my main questions on CHK1 are: 1. Will trials start (I.e. did pre clinical go ok) 2. How will they be funded 3. What combinations of treatment will be included as this will give us a more acurate idea on just how 'broadly applicable' CHK1 can be.
Fortunately the answers to all of these should be known in 3 to 6 months.
Let's be honest. This is the biotechnology industry and anyone who is in here for a quick buck at this time is kidding themselves on. Like everyone else on this board I have invested but I am under no illusion that this is going to mature for a long time. And I don't mean the large spike we had a few years ago, I mean a true value on a priceless product that is being developed to save lives and not just to make us money. Keeping in mind this may never come to anything but I for one am happy to wait up to the 10 years for this to make or break as I strongly believe in this company.
Not really, it's more like gardening, plant the seed and wait for it to germinate. Well, the seed has germinated, the branches are beginning to grow and it's just a question of time before the first fruits can be harvested.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.